MRP : 245
AGIFIX-CV 325 is indicated for the treatment of infections caused by resistant bacteria:
AGIFIX-CV is not advocated for those with a history of hypersensitivity to beta-lactams, e.g:penicillins and cephalosporins.
Precautions & Warnings
Before therapy with AGIFIX-CV is instituted careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins or other drugs. Cefixime as with other broad-spectrum antibiotics should be prescribed with caution in individuals with a history of colitis. Increase in prothrombin times occur and therefore care should be taken in patients receiving anticoagulant therapy. No adequate and well-controlled studies in pregnant women have been reported so AGIFIX-CV should therefore not be used in pregnancy or in nursing mothers unless considered essential by the physician.
The most frequent adverse effect is gastrointestinal (GI) complaints, and diarrhea incidence is 16%. Other side effects include hypersensitivity reactions, liver / renal dysfunction, headaches, dizziness, seizures, hematopoietic changes, genital pruritus, vaginitis, candidiasis.
Carbamazepine: Elevated carbamazepine levels have been reported when cefixime is administered concomitantly.
Warfarin and Anticoagulants: Increased prothrombin time with or without clinical bleeding, has been reported when cefixime is administered concomitantly.
Oral Contraceptives: Cefixime may interfere with the effectiveness of birth control pills.
Glucose Test: A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets.
Coombs test: A false positive direct Coombs test has been reported during treatment with cephalosporin antibiotics.
Adults: The recommended dose of AGIFIX-CV is 200 – 400mg daily. This may be given as once daily dose or in two divided doses every 12 hours.
AGIFIX-CV 325 – Alu Alu of 10 tablets.